Elanco Launches Befrena, Extending Lead in $1.3B Canine Dermatology Market
Event summary
- Elanco launched Befrena (tirnovetmab), an anti-IL-31 monoclonal antibody for canine allergic dermatitis, on May 18, 2026.
- Befrena offers 6-8 weeks of itch relief, longer than the 4-8 weeks provided by competitor lokivetmab.
- The product received USDA approval in December 2025 and is now in phased launch with select veterinarians.
- Elanco is the only pet health company with two USDA-approved monoclonal antibody products (Befrena and Trutect).
The big picture
Elanco's launch of Befrena solidifies its position in the $1.3 billion U.S. canine dermatology market, leveraging its expertise in monoclonal antibodies. The product's extended dosing interval and rapid itch relief address a significant unmet need, particularly as allergy seasons intensify. This move underscores Elanco's strategic focus on innovation in pet health, following its successful launch of Trutect for canine parvovirus.
What we're watching
- Market Penetration
- The pace at which Befrena gains adoption among veterinarians and pet owners will determine its market share against established treatments like lokivetmab.
- Manufacturing Scaling
- Elanco's ability to scale bioreactor production will be critical to meeting demand and supporting the product's phased launch.
- Competitive Response
- Whether competitors will introduce longer-lasting or more effective treatments to challenge Befrena's differentiated dosing interval.
Related topics